Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE TREE: Empagliflozin vs Dapagliflozin
NCT06642272Phase 4Recruiting
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, dapagliflozin in type 2 diabetes mellitus (T2DM), heart failure (HF), chronic kidney disease (CKD), sponsored by Herlev & Gentofte Hospital. Started Oct 2024; status: recruiting.
02
Drugs
empagliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06642272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642272.